Additional Indications Below for Module 4 and 5 clinical trials at UCSF
1 in progress, 0 open to eligible people
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Sorry, not currently recruiting here
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
San Francisco, California and other locations
Our lead scientists for Additional Indications Below for Module 4 and 5 research studies include Pamela Munster.